{"entity":{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","aka":["Suzhou Forlong Biotechnology Co., Ltd"],"tldr":"Suzhou Forlong Biotechnology is a China-based biotechnology company running 2 late-stage cancer trials of FL115 in bladder & urothelial cancer.","summary":"Suzhou Forlong Biotechnology, based in Suzhou, China, is a biotechnology company. Suzhou Forlong Biotechnology (also styled Furong Biotech) develops next-generation cytokine drugs based on synthetic immunology, using platforms for long-acting optimisation, Fc engineering, AI-driven discovery and synthetic cytokine creation. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing FL115 in bladder & urothelial cancer. The largest, NCT07131202 (A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumours), plans to enrol 130 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.forlongbiotech.com"},{"label":"ClinicalTrials.gov: trials led by Suzhou Forlong Biotechnology","url":"https://clinicaltrials.gov/search?lead=Suzhou%20Forlong%20Biotechnology%20Co.%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07131202","nct07122414"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.forlongbiotech.com","founded":2019,"stage":"growth","investors":[],"funding":[]},"route":"/companies/suzhou-forlong-biotechnology/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct07131202","kind":"trial","name":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors","route":"/trials/nct07131202/"},{"id":"nct07122414","kind":"trial","name":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","route":"/trials/nct07122414/"}]}}